Company’s 36-month beta value is 1.93.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as
Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX)’s stock price has plunge by -2.10relation to previous closing price of 4.77. Nevertheless, the company has seen a 1.30% surge
The 36-month beta value for BCRX is at 1.94. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2
The stock has a 36-month beta value of 1.90. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as
Additionally, the 36-month beta value for BCRX is 1.91. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2
© 2024, Fueled by Smart TechOne
